Financial Review: Abeona Therapeutics (ABEO) versus Cleveland BioLabs (CBLI)
Abeona Therapeutics (NASDAQ: ABEO) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.
This is a breakdown of current recommendations and price targets for Abeona Therapeutics and Cleveland BioLabs, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Abeona Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500.
Valuation and Earnings
This table compares Abeona Therapeutics and Cleveland BioLabs’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Abeona Therapeutics||$890,000.00||780.54||-$21.87 million||($0.66)||-22.50|
|Cleveland BioLabs||$3.52 million||12.05||-$2.65 million||($0.87)||-4.32|
Cleveland BioLabs has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Cleveland BioLabs, indicating that it is currently the more affordable of the two stocks.
This table compares Abeona Therapeutics and Cleveland BioLabs’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
42.0% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Cleveland BioLabs shares are owned by institutional investors. 6.8% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Cleveland BioLabs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Abeona Therapeutics beats Cleveland BioLabs on 9 of the 13 factors compared between the two stocks.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Cleveland BioLabs Company Profile
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.